The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.

Authors:
Alison J Dawson
Alison J Dawson
University of Hull
United Kingdom
Thozhukat Sathyapalan
Thozhukat Sathyapalan
University of Hull
Professor of Endocrinology
Hull | United Kingdom
Rebecca Vince
Rebecca Vince
University of Hull
United Kingdom
Anne-Marie Coady
Anne-Marie Coady
University of Hull
United Kingdom
Ramzi A Ajjan
Ramzi A Ajjan
University of Leeds
United Kingdom
Eric S Kilpatrick
Eric S Kilpatrick
University of Hull
United Kingdom
Stephen L Atkin
Stephen L Atkin
University of Hull
United Kingdom

Front Endocrinol (Lausanne) 2019 2;10:189. Epub 2019 Apr 2.

Weill Cornell Medicine Qatar, Education City, Doha, Qatar.

Polycystic ovary syndrome (PCOS) is associated with an adverse cardiovascular risk profile including a prothrombotic state. Exenatide has been shown to be effective at improving insulin sensitivity and weight loss in PCOS; therefore this study was undertaken to assess its effects on weight, endothelial function, inflammatory markers, and fibrin structure/function in overweight/obese women with PCOS. Thirty overweight/obese anovulatory women with all 3 Rotterdam criteria received exenatide 5 mcg bd for 4 weeks then 10 mcg bd for 12 weeks. The primary outcome was change in weight; secondary outcomes were changes in endothelial function [Reactive Hyperemia-Peripheral Arterial Tonometry (RH-PAT)], serum endothelial markers (ICAM-1, VCAM-1, E-selectin, and P-selectin), change in inflammation (hsCRP), and alteration in clot structure and function [maximum absorbance (MA), and time from full clot formation to 50% lysis (LT)]. Twenty patients completed the study. Exenatide reduced weight 111.8 ± 4.8 to 108.6 ± 4.6 kg = 0.003. Serum endothelial markers changed with a reduction in ICAM-1 (247.2 ± 12.9 to 231.3 ± 11.5 ng/ml = 0.02), p-selectin (101.1 ± 8.2 to 87.4 ± 6.6 ng/ml = 0.01), and e-selectin (38.5 ± 3.3 to 33.6 ± 2.6 ng/ml = 0.03), without an overt change in endothelial function. Inflammation improved (CRP; 8.5 ± 1.4 to 5.6 ± 0.8 mmol/L = 0.001), there was a reduction in clot function (LT; 2,987 ± 494 to 1,926 ± 321 s = 0.02) but not clot structure. Exenatide caused a 3% reduction in weight, improved serum markers of endothelial function, inflammation, and clot function reflecting an improvement in cardiovascular risk indices in these women with PCOS. This suggests exenatide could be an effective treatment for obese women with PCOS. ISRCTN81902209.

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fendo.2019.00189
Publisher Site
http://dx.doi.org/10.3389/fendo.2019.00189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454834PMC
April 2019
6 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 3, 2019, 11:45 am EST

Publication Analysis

Top Keywords

endothelial function
16
cardiovascular risk
12
women pcos
12
serum endothelial
8
mcg weeks
8
ovary syndrome
8
endothelial markers
8
exenatide effective
8
clot structure
8
polycystic ovary
8
clot function
8
function inflammation
8
function
7
exenatide
6
endothelial
6
markers
5
clot
5
weight
5
pcos
5
women
5

References

(Supplied by CrossRef)
Endothelial dysfunction: does it matter?
Celermajer et al.
J Am Coll Cardiol. 1997

Similar Publications